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Abstract
Despite its high diagnostic performance, the use of breast MRI in the preoperative setting is controversial. It has the potential for
personalized surgical management in breast cancer patients, but two of three randomized controlled trials did not show results in
favor of its introduction for assessing the disease extent before surgery. Meta-analyses showed a higher mastectomy rate in
women undergoing preoperativeMRI compared to those who do not. Nevertheless, preoperative breast MRI is increasingly used
and a survey from the American Society of Breast Surgeons showed that 41% of respondents ask for it in daily practice. In this
context, a large-scale observational multicenter international prospective analysis (MIPA study) was proposed under the guidance
of the European Network for the Assessment of Imaging in Medicine (EuroAIM). The aims were (1) to prospectively and
systematically collect data on consecutive women with a newly diagnosed breast cancer, not candidates for neoadjuvant therapy,
who are offered or not offered breast MRI before surgery according to local practice; (2) to compare these two groups in terms of
surgical and clinical endpoints, adjusting for covariates. The underlying hypotheses are that MRI does not cause additional
mastectomies compared to conventional imaging, while reducing the reoperation rate in all or in subgroups of patients. Ninety-six
centers applied to a web-based call; 36 were initially selected based on volume and quality standards; 27 were active for
enrollment. On November 2018, the target of 7000 enrolled patients was reached. The MIPA study is presently at the analytic
phase.
Key Points
• Breast MRI has a high diagnostic performance but its utility in the preoperative setting is controversial.
• A large-scale observational multicenter prospective study was launched to compare women receiving with those not receiving
preoperative MRI.
• Twenty-seven centers enrolled more than 7000 patients. The study is presently at the analytic phase.
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Introduction
Breast-conserving surgery (BCS) with whole breast irradia-
tion is the best option for operable breast cancers, comparable
to mastectomy in terms of survival [1, 2], with generally better
psychosocial outcomes. However, after BCS, the risk of loco-
regional recurrences or new ipsilateral/contralateral cancers is
1.0 to 1.5% per year for 15–20 years [3]. In addition, the rate
of positive/close margins after BCS is 26–30% [4, 5] usually
leading to reoperation.
The role of preoperative contrast-enhanced breast MRI
emerged in this surgical context. It showed an unparalleled
sensitivity in comparison with mammography and/or ultra-
sound [6–12]. When compared to double-reading mammog-
raphy in 99 mastectomies [13], its sensitivity (81%) was sig-
nificantly higher than that of mammography (66%). A large
study [14] reported over 95% sensitivity and specificity while
another study [15] reported that 23% of MRI-detected addi-
tional tumors were larger and 5%more biologically important
than the index cancer. In meta-analyses, the frequency of
MRI-detected additional cancers was around 20% [16], in
agreement with the high rate of multifocal/multicentric can-
cers found at pathology of mastectomy specimens [17], while
the rate of additional contralateral cancers was 4–5% [16, 18].
Breast MRI has been advocated to personalize the surgical
management, reducing reoperation rate and early-detecting
contralateral cancers, with a potential for improving disease-
free survival. However, two of three randomized controlled
trials (RCT) [19, 20] did not confirm better surgical outcomes,
and the third [21], focusing on relatively younger women was
in favor of MRI. Furthermore, a recent RCT of 360 patients
with ductal carcinoma in situ failed to show a significant re-
duction of the reoperation rate in the MRI group over the
control group (20% versus 27%) highlighting the need for
large sample sizes to examine benefits in subgroups [22].
A meta-analysis [23] found a first-line mastectomy rate
significantly higher for the MRI group (16%) than for the
no-MRI group (8%), a similar reoperation rate (12% versus
11%, respectively), and an overall (first-line plus secondary)
mastectomy rate significantly higher for the MRI group (26%
versus 18%, respectively). In patients with invasive lobular
histology, the first-line mastectomy rate was 31% versus
25%, the reoperation rate 11% versus 18%, and the overall
mastectomy rate 43% versus 40%, respectively (with signifi-
cance borderline or dependent on adjustments).
An individual patient data meta-analysis [24] showed that
the 8-year local and distant recurrence-free survival did not
significantly differ between patients locally staged with or
without MRI. Another meta-analysis [25] did not find evi-
dence that MRI improved surgical outcomes while the odds
for ipsilateral mastectomy (odds ratio [OR] 1.39) and contra-
lateral prophylactic mastectomy (OR 1.91) were significantly
increased. In the subgroup of invasive lobular histology, MRI
was not associated with an increase in mastectomy rate (OR
1.0) but with a reduced probability of reoperation (OR 0.65),
although not at statistically significant levels.
Data from these studies are summarized in Table 1.
The discussion regarding the utility of preoperative MRI
has not ended yet, with arguments in favor [26, 27] and
against [28–30], and remains an unsolved aspect of breast
cancer management [31, 32]. While MRI certainly improves
disease extent definition, there is conflicting evidence and
uncertainty on whether and in whom it is beneficial,
underscoring the need for additional evidence.
The American Society of Breast Surgeons [33] suggests
“Don’t routinely order breast MRI in new breast cancer
patients.” However, regardless of evidence and recommenda-
tions, a survey from that society [34] showed that 41% of
responding surgeons use preoperative MRI in daily practice.
Another survey [35] showed a surgeons’ propensity for
requesting MRI in case of (in decreasing order) BRCA muta-
tions; familial/personal breast cancer history; dense breasts; age
< 40; axillary nodal involvement; mammographically occult
tumor; multifocal/multicentric disease at conventional imaging;
invasive lobular histology; triple-negative cancer; T2–T3 stage;
candidates for mastectomy requesting breast-conserving sur-
gery (BCS); and radiologist’s discretion.
A prospective multicenter trial to solve
the conundrum
An international group (European Network for the
Assessment of Imaging in Medicine, EuroAIM; https://
www.eibir.org/ini t iat ives/euroaim/) established a
collaborative plan to conduct a large-scale observational mul-
ticenter international prospective analysis (MIPA) study to be
performed in institutions providing high-volume breast MRI
and high-quality standards. The aimswere (1) to prospectively
and systematically collect data on consecutive women with a
newly diagnosed first breast cancer, who are not candidates to
neoadjuvant therapy, and who are offered MRI (MRI group)
or not (no-MRI group) as part of local breast cancer manage-
ment; (2) to compare these two groups in terms of character-
istics, and surgical and clinical endpoints. The underlying
hypotheses are that MRI does not cause additional mastecto-
mies compared to conventional imaging, while reducing the
reoperation rate in all or subgroups of patients.
International open call
The MIPA study was undertaken under the initiative and re-
sponsibility of the EuroAIM and endorsed by the European
Society of Breast Imaging (EUSOBI). Bayer Healthcare pro-
vided an unconditional research grant for the conduct of the
study.
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In mid-2012, an open call was published on the EuroAIM
website and circulated within the EUSOBI members.
Applying centers had to confirm a series of preliminary con-
ditions pertaining to quality of MRI, focusing on equipment
and workload (Table 1 of Supplemental material). Moreover,
they had to anticipate (1) the approximate number of patients
potentially recruitable; and (2) the local rate of MRI per-
formed in women newly diagnosed with breast cancer.
Once selected, centers provided technical details of the
MRI protocols applied locally. The coordinating center
approved only MRI protocols following technical recommen-
dations issued by international societies such us the European
Society of Breast Cancer Specialists (EUSOMA) [36], the
EUSOBI [37], and the American College of Radiology [38].
Details are shown in Table 2.
Study design and population
MIPA is a multicenter observational prospective study enroll-
ing women newly diagnosed with breast cancer. No experi-
mental intervention was planned. Centers were free to perform
or not perform MRI according to local practice. Thus, two
concurrent groups resulted ex post by whether women
underwent preoperative staging using conventional imaging
only (no-MRI group) or also received contrast-enhanced MRI
(MRI group) in addition to conventional imaging,
representing real-world breast cancer management (study reg-
istration ISRCTN41143178).
The study was conducted in accordance with the
Declaration of Helsinki and was firstly approved on January
29, 2013, by the ethics committee at the coordinating center
(protocol number 2784). Thereafter, ethical approval was
obtained at each center. All participants signed an informed
consent allowing the use of their data according the observa-
tional design.
The coordinating center at the Research Hospital (IRCCS)
Policlinico San Donato (San Donato Milanese, Milan, Italy)
was charged to ensure that the research data were accurate,
complete, and consistent. The description of the database set
up is reported in the supplemental material.
The study population included women aged 18 to 80 years
newly diagnosed with a first breast cancer amenable to upfront
surgery. Exclusion criteria included indication to neoadjuvant
therapy, pregnancy, personal history of invasive or ductal in
situ breast cancer, personal history of any cancer, evidence of
distant metastases at enrollment, and inability to provide in-
formed consent. Women with contraindications to MRI or to
gadolinium-based contrast agents were included in the no-
MRI group. The study flowchart is shown in Fig. 1.
Study endpoints and statistical analysis
Primary surgical endpoints for the two groups are (1) the rate
of mastectomies actually performed; and (2) the reoperation
rate for close or positive margins among patients undergoing
BCS. A secondary surgical endpoint for the MRI group only
is the rate of change, after MRI, to more extended unilateral
BCS (wider excision or multiple excisions) or to less extended
BCS, or from unilateral BCS to bilateral BCS or vice versa.
Secondary clinical endpoints for the two groups are the rate of
(1) ipsilateral recurrences, (2) contralateral breast cancers, and
(3) distant metastases at 5-year follow-up.
Assuming a reoperation rate due to positive/close margins
in the no-MRI group of 20%, we anticipated a reoperation rate
in the MRI group of 15%. To detect this reduction with an α
error of 0.05 and 90% statistical power, 1250 women in each
group (total 2500 women) should have been enrolled. To al-
low for 10% losses/missing data during follow-up, 1400 × 2 =
2800 women would have been needed. As the primary end-
point (reoperation rate) will be compared also in the subgroup
of patients with ductal carcinoma in situ, which represents
about 20–25% of all breast cancers [39, 40], the target sample
size was set at 7000 patients to support subgroup analyses.
Considering the large dataset, the sample size will allow ex-
plorative analyses for further hypotheses including other his-
tology subgroups (e.g., lobular).
The two concurrent groups will be initially compared in
terms of baseline characteristics such as demographics and
breast density. As both groups receive conventional imaging,
baseline characteristics include the surgical plan based on con-
ventional imaging only, as defined by the multidisciplinary
team or through direct interaction between radiologists and
surgeons. As this is an observational study, this comparison
can provide an insight on criteria used by physicians when
ordering preoperative breast MRI that might cause selection
Table 2 Preoperative breast MRI: technical requirements and imaging
protocols of the MIPA study
Technical requirements
Magnetic field strength ≥ 1.5 T
Gradients power ≥ 20 mT/m
Channels of dedicated coil ≥ 4
Technical protocol
One of the following T2-weighted sequences (axial or sagittal):
– Fast/turbo spin-echo ± fat-sat
– Short tau inversion recovery (STIR)
– Spectral pre-saturation with inversion recovery (SPIR)
Contrast agent type and dose: extracellular gadolinium-based contrast
agent, 0.1 mmol/kg
Dynamic study (2D or 3D T1-weighted gradient-echo sequence ±
fat-saturation, axial or sagittal)
– Slice thickness ≤ 3 mm
– In-plane resolution ≤ 1.5 mm2 (preferably ≤ 1 mm2)
– Temporal resolution ≤ 120 s
2D two-dimensional, 3D three-dimensional
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biases. To this aim, the odds ratio (OR) of plan for mastectomy
after conventional imaging will be calculated for the MRI
group relative to the no-MRI group.
Depending on distributions, comparisons of continuous var-
iables will be carried out using Student t test or Mann-Whitney
U test for independent data, and using χ2 test for categorical
variables. Variables that will be shown to be significantly dif-
ferent between the two groups will be considered as covariates
when the two groups will be compared in analyses.
For the primary endpoints, statistical analysis will be per-
formed on a per-patient basis. The two concurrent groups will
be compared by calculating the OR for mastectomy for the
MRI group over the no-MRI group, raw and adjusted for
covariates. A similar analysis will be carried out for the
reoperation rate in patients undergoing BCS. Moreover, as in a
before-after intra-individual study design, the rate of mastec-
tomy before and afterMRI in theMRI group will be compared
using the McNemar test for paired data. Hence, changes of
treatment planning from BCS based on conventional imaging
as well as on available clinical examination and pathological
data to mastectomy after MRI may compensate for the oppo-
site change.
For secondary surgical endpoints regarding the MRI group
only, per-breast distributions will be calculated using the same
methodology described above for primary endpoints.
Conversely, secondary clinical endpoints will be determined
on a per-patient basis. Further analyses will be performed,
including investigation of homogeneity across centers and
temporal trends for both primary and secondary endpoints.
Timeline
In about 2 months following the open call, a total of 96 centers
applied from all over the world. Thirty-six centers were ini-
tially selected based on pre-defined criteria: (1) the full respect
of quality standards requested by the call (see Table 1 of
Supplemental material); (2) the anticipated total number of
patients that could potentially be enrolled in the center; and
(3) the anticipated rate of patients that usually undergo preop-
erative MRI at the center. This allowed careful selection of
centers among those with the highest volumes of breast MRI
whilst also ensuring to balance the expected rate of MRI at
about 50%.
After the study had begun, nine centers abandoned the
study or never enrolled patients, four centers started the en-
rollment with very few patients but did not provide valid data;
four centers were added later to replace the vacancies, so 27
centers were actively enrolling. The list of the 27 active cen-
ters is shown in Table 3.
During the pilot procedure run, few concerns were raised
from local investigators and were fixed promptly. Valuable
input came from centers for a further refinement of the elec-
tronic case report form, in particular, due to wording that was
potentially misleading. The first woman was enrolled in
June 2013. On November 30, 2018, the target of 7000 en-
rolled breast cancer patients was reached. The distribution of
patients enrolled in each participating center is shown in
Table 3. The enrolment is ended, while the follow-up should
end by November 2023. Data cleaning and statistical analysis
Fig. 1 Flowchart of the prospective observational multicentre MIPA study. Allocation to MRI was based on local clinical practice
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of the baseline data is being conducted and the first paper with
the main results will be submitted by 2020.
Conclusion
The use of preoperative MRI of the breast is controversial,
mainly because it can affect the surgical planning and yet
the evidence on its effect and clinical benefit has been discor-
dant. The MRI diagnosis of additional cancers can change a
BCS into mastectomy also when those lesions would be suc-
cessfully treated by whole breast irradiation and/or systemic
therapy, working against reducing surgical aggressiveness.
In the first years of breast MRI, the variable reported spec-
ificity [41, 42] combined with a limited use of target ultra-
sound and the lack of MRI-guidance for biopsy/localization
also made MRI false-positives difficult to manage [19]. To
transfer knowledge about disease extent demonstrated by
MRI, performed in the prone position, to the surgical theater
with the patient in supine position, is not easy [43]. A learning
curve gradually improved the performance of radiologists in
using targeted ultrasound [44], second-look mammography/
tomosynthesis [45], andMRI-guidance [46]. Surgeons as well
needed time to learn how to exploit the additional information
from preoperative breast MRI.
The application of evidence-based medicine [47] is diffi-
cult in this setting. Preoperative MRI joins three clinical is-
sues: (1) measuring the size of the index lesion; (2) searching
for ipsilateral additional cancers; and (3) screening for contra-
lateral cancers. While the first requires cohort studies correlat-
ing sizes at MRI and histopathology, the third is a screening-
like task, theoretically needing RCTs before implementation
[47, 48]; the second issue is arguably in the middle.
Considering the treatments still prevalent for breast cancer
Table 3 List of the 27 centers
participating in the MIPA study
and number of enrolled patients
Center Enrolled
patients
Radboud University Medical Center, Nijmegen, The Netherlands 956
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Italy 619
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 504
University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK 485
Hospital Universitario Reina Sofia, Cordoba, Spain 439
Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey 400
Medical University of Vienna, Vienna, Austria 368
Sociedade Beneficente De Senhoras, Hospital Sirio Libanes, Sao Paulo, Brazil 301
Maastricht University Medical Center, Maastricht, The Netherlands 265
IEO, Istituto Europeo di Oncologia, Milan, Italy 248
Radiologic Institute University, Erlangen, Germany 246
University Hospital, Tübingen, Germany 244
IRCCS Azienda Ospedaliera Universitaria San Martino, Istituto Nazionale per la Ricerca sul
Cancro, Genoa, Italy
233
Antwerp University Hospital, Antwerp, Belgium 228
Maatschap Radiologie Oost-Nederland, Oldenzaal, The Netherlands 207
Institut de cancérologie Gustave-Roussy 195
Sapienza University, Policlinico Umberto I, Rome, Italy 191
Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands 178
Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy 166
The Breast Center of Northwest Arkansas, Fayetteville, USA 142
Central Military Hospital, Budapest, Hungary 132
IRCCS Ospedale San Raffaele, Milan, Italy 113
Hospital de la Ribera, Alzira, Spain 95
Royal Perth Hospital, Perth, Australia 66
University Hospital, Münster, Germany 66
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy 40
BHR Hospitals NHS Trust, Romford, UK 27
Total 7154
The study was coordinated by the Research Hospital (IRCCS) Policlinico San Donato, San Donato Milanese,
Milan, Italy
Eur Radiol
including whole breast irradiation following BCS, mastecto-
my for multicentric cancers, and variable systemic therapy,
effects of preoperative MRI are difficult to assess.
The strength of theMIPA study is its special design. In fact,
two designs were combined to derive the highest evidence
possible: a case-control approach allowing the comparison
of women undergoing MRI and women not undergoing
MRI, and a before-after approach to have a direct measure
of the MRI impact on surgery. The well-known limitations
of the case-control approach will, in turn, result in an advan-
tage for the MIPA study. In fact, whatever the difference be-
tween the two groups in terms ofmastectomy/reoperation rate,
the knowledge of the treatment plan after conventional imag-
ing even in the MRI group will provide evidence on possible
selection bias. From the other side, the before-after approach
will allow not only the estimation of the additional mastecto-
my rate independently prompted by MRI (that may also be
negative, meaning that MRI reduces the mastectomy rate) but
also the evaluation of the changes of surgical extension in
those women undergoing BCS, from less extensive to more
extensive and vice versa.
Although the lack of randomization is a limitation of the
MIPA study, it can be considered an effective and pragmatic
way to provide evidence that is closer to the real-world ap-
proach [49, 50]. Especially from the intra-individual part of
the study (comparing the plan for mastectomy before and after
MRI), we will provide a clear insight into MRI’s impact on
patients’ surgical management. Moreover, thanks to large
number of patients and data that were collected, we will be
able to answer several other questions. In particular, subgroup
analyses will ascertain which patients will benefit the most
from preoperativeMRI. Correlation analyses will instead clar-
ify the role of potential predictors, while follow-up data will
provide evidence on cancer recurrences.
In conclusion, a large-scale real-world prospective multi-
center study investigating the role and effect of MRI in the
preoperative setting was launched internationally. This exem-
plar of the joint efforts of 27 centers enabled the target of 7000
women with newly diagnosed breast cancer to be reached and
the study is presently at the analytic phase.
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